Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 1
2008 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Antiretroviral-drug resistance among patients recently infected with HIV.
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. Little SJ, et al. N Engl J Med. 2002 Aug 8;347(6):385-94. doi: 10.1056/NEJMoa013552. N Engl J Med. 2002. PMID: 12167680 Free article.
Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy.
Jin X, Ramanathan M Jr, Barsoum S, Deschenes GR, Ba L, Binley J, Schiller D, Bauer DE, Chen DC, Hurley A, Gebuhrer L, El Habib R, Caudrelier P, Klein M, Zhang L, Ho DD, Markowitz M. Jin X, et al. J Virol. 2002 Mar;76(5):2206-16. doi: 10.1128/jvi.76.5.2206-2216.2002. J Virol. 2002. PMID: 11836398 Free PMC article. Clinical Trial.
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination.
Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, Deschenes GR, Ramanathan M Jr, Barsoum S, Vanderhoeven J, He T, Chung C, Murray J, Perelson AS, Zhang L, Ho DD. Markowitz M, et al. J Infect Dis. 2002 Sep 1;186(5):634-43. doi: 10.1086/342559. Epub 2002 Aug 9. J Infect Dis. 2002. PMID: 12195350 Clinical Trial.
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection.
Leigh Brown AJ, Frost SD, Good B, Daar ES, Simon V, Markowitz M, Collier AC, Connick E, Conway B, Margolick JB, Routy JP, Corbeil J, Hellmann NS, Richman DD, Little SJ. Leigh Brown AJ, et al. J Virol. 2004 Mar;78(5):2242-6. doi: 10.1128/jvi.78.5.2242-2246.2004. J Virol. 2004. PMID: 14963120 Free PMC article.
Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course.
Prada N, Davis B, Jean-Pierre P, La Roche M, Duh FM, Carrington M, Poles M, Mehandru S, Mohri H, Markowitz M. Prada N, et al. J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):117-22. doi: 10.1097/QAI.0b013e3181869a9b. J Acquir Immune Defic Syndr. 2008. PMID: 18769360 Free PMC article.